Q4 2020 Syneos Health Inc Earnings Call

February 18, 2021

[music].

Good morning, and welcome to the seniors health fourth quarter and full year 'twenty 'twenty earnings Conference call. At this time, all participants are in a listen only mode.

Later, we will conduct a question and answer session and instructions will be given at that time.

I would like to hand, the conference over to Ronnie Speight.

Senior Vice President of Investor Relations.

Please go ahead Sir.

Good morning, everyone with me on the call today are Alistair Macdonald, our Chief Executive Officer, Jason Meggs, Our Chief Financial Officer, Michelle Keefe, our president of commercial solutions, and Paul Colvin, our president of political.

Solution.

In addition to the press release, a slide presentation corresponding to our prepared remarks.

Available on our website at Investor Day, <unk> health Dot com.

Remarks that we make about future expectations plans growth anticipated financial results and prospects and our expectations regarding the COVID-19 pandemic constitute forward looking statements for purposes of the Safe Harbor provisions under the private Securities Litigation Reform Act of 1995, and we disclaim.

Any obligation to update them.

Actual results may differ materially from those indicated by these forward looking statements as a result of various important factors. These factors are discussed in the risk factors section of our form 10-K for the year ended December 31 2020.

During this call, we will discuss certain non-GAAP financial measures, which exclude the effects of events and transactions, we consider to be outside of our core operations.

These non-GAAP measures should be considered a supplement to and not a replacement for measures prepared in accordance with GAAP.

For a reconciliation of non-GAAP financial measures with the most directly comparable GAAP measures. Please refer to the appendix of our presentation.

I would now like to turn the call over to Alistair Macdonald Alastair.

Thanks, Tony Good morning, everyone and thank you for joining US today I Hope you and your families are safe and in good health.

I am pleased to report that we delivered a solid fourth quarter and full year financial results as we continue our recovery from the impacts of COVID-19.

As demonstrated by our strong sales performance in the quarter, which capped off a record year of award a growing portfolio of innovative and integrated product development solution continues to resonate with customers of all sizes.

Revenue across both segments grew sequentially overall profitability was also strong growing both sequentially and on a year over year basis.

We continue to deliver on the value creation plan outlined at our Investor event in December executing on our key growth strategies are further penetrating large pharma enhancing our leadership position with smid customers and accelerating our innovative <unk> and full service commercial offerings.

We expect strong growth in both our segments in 2021, which will become most apparent from the second quarter onwards.

Primarily driven by the robust New awards added to our backlog since late 2019, beginning to ramp along with our Covid vaccine trials.

Our <unk> backlog now exceeds $10 billion, providing us with a consistent revenue pipeline and highlighting our confidence in the long term strength of our business.

We have maintained a balanced approach to capital deployment.

<unk> focused on strategic M&A activity that will help expand our access to new markets and add key services to our portfolio.

During the fourth quarter, we closed the acquisition of <unk>.

Which provides us with an expanded presence in the emerging biopharma market with strong biotech funding and innovation all driving double digit growth.

We are also excited about our more recent acquisition of dealing with research group, a leading global provider of clinical research home Health services, which Covid 46 countries and enabled clinical trial participation from the comfort and safety of the patient Shanghai Covid.

COVID-19 has accelerated the decentralization of health care delivery and the need for in home clinical trial services.

And we believe this trend is favorable as it relates to demand for <unk> services.

Ending with expense with scale and capabilities of our decentralized solutions, allowing our customers to realize efficiencies and patient recruitment and engagement with improved patient access and diversity.

Now for the key highlights from the quarter.

First we closed Q4 with strong net new business awards, resulting in book to Bill ratios of 152 times with clinical solutions 163 times for commercial solutions on 155 times in total.

During full year 2020, we achieved a record $5 9 billion of net awards and an aggregate book to Bill ratio of 133 times.

<unk> book backlog growth and record ending backlog.

Second we experienced strong profitability for the fourth quarter with three 3% year over year.

Adjusted EBITDA growth and a 160 basis point adjusted EBIT margin increased to 17, 1%.

This brings our full year adjusted EBITDA margins of 14, 3%, a 50 basis point increase over 2019.

And third we generated another quarter of growth operating cash flow at $114 3 million.

<unk> and a record total of $425 5 million for.

For the full year 2020, further strengthening our overall financial position and liquidity.

Now getting into the detail of our results.

During the fourth quarter, we continued to sequentially recover from the impacts of COVID-19, with total revenue growth of three 7% compared to the third quarter.

Nickel solutions revenue continued its sequential recovery growing three 2% over the third quarter our.

Our clinical team also delivered a strong fourth quarter of net awards, resulting in net awards growth of 13, 3% per the full year.

<unk> clinical net awards were a record $4 7 billion, resulting.

Resulting in a strong TTM book to Bill ratio of 142 times and year over year backlog growth of 24, 6%, including the impact of acquisitions.

Clinical solutions is well positioned to see accelerating revenue growth in 2021, as a result of the strong backlog growth and robust pipeline.

We also won over 80 COVID-19 related clinical projects. During 2020. These represent approximately 7% of gross awards for 2020, and we continue to see a substantial pipeline of additional COVID-19 related opportunities.

While we continue to see some operational delays in cities, we have not experienced any meaningful cancellations as a consequence of COVID-19.

The pandemic continues to drive a high utilization of remote monitoring and lower patient enrollment in some therapy areas.

We anticipate a return to normal levels as we progress through 2021.

Turning now to commercial solutions revenue grew five 4% compared to the third quarter, including sequential growth across all businesses.

Our commercial team once again had a strong fourth quarter and awards, resulting in a one $1 6 billion with net awards and a book to Bill ratio of one five times for full year 2020.

Importantly, our full service commercial awards more than doubled in 2020 compared to 2019, demonstrating that our integrated delivery model is increasingly penetrate in the market, particularly with estimated customer base.

This award performance drive deployment solutions backlog to a record level with growth of 4% compared to the fourth quarter of 2019.

Deployment solutions also executed a record number of new teams saw in 2020 spanning our diverse field team resources and our virtual engagement center.

Although net awards and book to Bill for 2020 were impacted by higher cancellations during the first half of the year.

Our commercial pipeline remains robust given the growing complexity of customer product strategy and the rapid pace of FDA new drug approvals.

We continue to deliver high levels of innovation side customer base, including the evolution of kinetic our modern customer engagement capability.

Kinetic combines insight intelligence and the omni channel expertise to strengthen relationships between sales teams and hcp's by targeted digital messaging.

<unk> hundred 60, a leading publication from marketing decision makers recently recognized digital amplifier, a key component of kinetic at an end of 2020.

An example of kinetic powerful impact includes enabling our customer to reach 80% of targeted hcp's. Despite the fact from personal access was not possible due to COVID-19.

It also creates a subsequent double digit prescription growth for those hcp's, who receive digital messaging that complemented personal messaging.

Kinetic results are increasingly driving new business with our customers, who are looking to transition to a more digital footprint contributing to 14% of our commercial gross awards during 2020.

Additionally, as we continue to deliver innovation across the <unk> spectrum. We are now leveraging connected cannot clinical programs to fuel innovation and patient outreach and recruitment for our customers.

While originally designed to optimize HCP outreach for our commercial sales teams. We are now working with our clinical customers to apply kinetic directive clinical project.

We're seeing very positive early results in patient engagement and enrollment by using connected digital amplification capabilities to enhance patient outreach and referrals through targeted physician.

We are accessing our dynamic assembly network to optimize a variety of data sources media sites and advanced analytics to customize a kinetic program for any given clinical therapy.

These innovations are further accelerating uptake of our insights driven product development model.

With that broader context, let me provide an update of some of the key operating metrics. We have highlighted in recent discussion.

Our clinical teams continue to see gradual improvement in their physical access to investigative site with about 70% of sites submitting some level of physical visits.

Similar to the third quarter. Some of these sites are facing capacity constraints, requiring a higher mix of remote monitoring visits than we previously anticipated.

Another 25% of our sites are now accessible only by some level of remote monitoring activities.

While about 5% of sites remaining accessible.

While science generally continues to be somewhat cautious amid localized increases in COVID-19 cases, we believe they are much better prepared to operate in this environment than they were in early 2020. Therefore, we expect <unk> to continue to improve gradually through the first half of 2021.

Our clinical teams are also experiencing continued improvement in the patient by patient enrollment and the startup of new clinical trials.

By early February new patient enrollment rates approached 120% of pre COVID-19 levels and new site Activations are trending at about 150% of pre COVID-19 levels.

We expect this strength in site activation and enrollment to try to ramp five core backlog along with our COVID-19 vaccine trials, creating year over year organic growth in the first quarter when excluding the impact of Reimbursable expenses, and our 2020 divestiture of contingent staffing.

Further we expect clinical solutions year over year organic revenue growth to accelerate in the second quarter of 2021 and for the balance of the year as we lap the initial 2020 impact from the pandemic.

Within commercial solutions, our deployment solutions field teams are executing on their omni channel strategy, while experiencing a gradual return to in person visits currently and about 65% of our territory.

The pace of this return to physical visits varies by customer with some of our large pharma customers, taking a more cautious stance on allowing net teams back into the field.

However, we continue to leverage our innovative connected capabilities to optimize HCP engagement through a combination of face to face and virtual sales team activities.

With total contact volume trending well above pre COVID-19 levels.

Importantly, we are seeing significant improvements in the average weekly productivity of our revenue through the utilization of kinetic handle the virtual capabilities.

The primary impact of COVID-19 has been reduced revenue from Reimbursable expenses, along with increased cancellations in the delayed startup of new customer program.

However, as we have health customers adapt to the current environment with our virtual capabilities New program startups have begun to accelerate which we expect to continue in 2021.

Our communications business continues to see increased demand for strategic integrated program.

Our unique combination of services across advertising public relations and medical communications enables customers to navigate the dynamic modern landscape, including the Eni and CSR programs COVID-19 response virtual engagement and other timely issues as.

This comprehensive approach is fueling growth in our full service commercial services, particularly with our smid customers.

In addition, the performance of our diverse consulting practices remains strong delivering double digit revenue growth in 2020, while building a record backlog of work entering 2021.

We expect to see year over year commercial solutions growth in the first quarter when excluding the impact of Reimbursable expenses and the medication adherence divestiture, primarily driven by continued new team sales and deployment solution.

We expect to see this year over year growth accelerate in the second quarter of 2021, as we begin to lap the impact of our elevate 2020 cancellations.

Before I turn the call over to Jason I want to welcome our new colleagues from <unk> and dealing with research group to the <unk> health team.

We want to offer my heartfelt thanks to the entire <unk> health community for their ongoing resilience focus and collaboration.

They continue to provide superior execution for our customers on the very challenging circumstances.

Jason will now provide additional comments on our financial performance and guidance Jason.

Jason.

Thank you Alastair and good morning, everyone.

Revenue for the fourth quarter of 2020 was $1, one 4 billion down six 1% and 7% in constant currency compared to the fourth quarter of 2019 on an adjusted basis.

Our clinical solutions revenue for the fourth quarter was $855 6 million down, 5% or five 9% in constant currency compared to the fourth quarter of 2019 on an adjusted basis.

These declines include a contribution of 140 basis points from acquisitions, partially offset by a headwind of 120 basis points from the second quarter divestiture of our contingent staffing business.

Clinical solutions revenue growth included a 470 basis point headwind from the slower recovery in Reimbursable expenses as more of our site visit activity remained remote patient enrollment continued to recover.

Our fourth quarter commercial solutions revenue was $284 5 million down nine 3% or nine 9% in constant currency.

The decline in commercial revenue was primarily due to the impact of elevated cancellations. During the first half of 2020 as well as the impact of COVID-19, including a disproportionate decline in Reimbursable expenses and delays in program starts.

This decline in Reimbursable expenses represented a 660 basis point headwind to commercial solutions year over year revenue growth in the fourth quarter.

Commercial solutions revenue for the fourth quarter outperformed our expectations, despite being negatively impacted by our divestiture of the medication adherence business.

In addition to the strengthening performance. We also have a robust pipeline of commercial opportunities highlighting the demand for our innovative solutions.

Adjusted EBITDA increased three 3% year over year.

Two $194 $8 million representing.

Representing an adjusted EBITDA margin of 17, 1% an increase of 160 basis points.

The increase in adjusted EBITDA margin for the fourth quarter was primarily a result of our synergies cost management initiatives, including forward balance and lower Reimbursable expenses.

For the full year 2020, adjusted EBITDA was $633 6 million a decrease of one 8% with margin increasing 50 basis points to 14, 3%.

With 2020 being our final year of measurement, we realize our targeted $140 million in total merger synergies prior to the impact of our strategic Reinvestments.

In addition, it is important to note that are on adjusted EBITDA grew by 10, 8% in 2020. This.

This was primarily driven by a reduction in restructuring transaction and integration related expenses as we wind down the bulk of our merger related cost.

We expect this trend to continue in 2021 with faster growth in unadjusted EBITDA as we continue our focus on cash flow conversion.

Adjusted diluted EPS of $1 11 for the fourth quarter increased by seven 8% year over year, primarily driven by the increase in adjusted EBITDA and lower interest expense.

For the full year 2020, we generated adjusted diluted EPS of $3 41.

Up five 6% compared to 2019, primarily driven by lower interest expense.

Our operations generated $114 $3 million in cash flow for the fourth quarter, bringing the full year to a record $425 5 million.

DSO for the quarter improved to 44 five days.

We ended the quarter with $271 $9 million of unrestricted cash and total debt outstanding of $2 $97 billion.

<unk> and net leverage of four three times.

Although net leverage increased primarily due to the financing of Center Act and Illingworth acquisitions, we remain committed to achieving our net leverage target of three to three five times by the end of this year.

During the quarter, we repaid $13 $5 million of our term all day and $200 million of our term loan b.

<unk> repurchased $8 $1 million of our outstanding shares.

Further we issued $600 million of senior notes bearing interest at 365%.

These notes mature in 2029, providing additional flexibility in our capital structure.

For the fourth quarter. The issuance of these notes resulted in an incremental $2 million of interest expense compared to our guidance.

Our non-GAAP effective tax rate for the fourth quarter and full year 2020 was 24%.

Given the benefit of our NOL deductions, our actual net cash outlay for income taxes in 2020 was approximately $23 million.

Turning now to our 2021 guidance this guidance contemplates our current view of the estimated impact of COVID-19 on our business.

Recognizing that factors related to COVID-19 are outside of the company's control.

Since we issued our initial guidance, we have seen some movement in foreign exchange rates.

That has resulted in incremental revenue tailwind from the full year, while also generating a partially offsetting headwind to our adjusted EBITDA.

Given that we are still early in the year and obscene only a limited potential impact we are maintaining our existing guidance ranges.

We continue to expect full year 2021 revenue in the range of $5, one 3 billion to $5 $33 billion.

Representing growth of 16, 1% to 26%.

This growth includes an estimated contribution from acquisitions of $540 to 580 basis points and a headwind from our 2020 divestitures of approximately 110 basis points.

With the strong revenue growth and the success of our forward bound programs.

Partially offset by headwinds from the exploration of our temporary cost saving measures in 2020.

We expect total adjusted EBITDA in the range of $745 million to $785 million.

This represents an adjusted EBITDA margin of 14, 5% to 14, 7% up 30 basis points from 2020 at the midpoint.

Lastly, we expect adjusted diluted EPS of $4 nine to $4 38.

Our year over year growth of 19, 9% to 28, 4%.

As noted on slide eight our guidance incorporates interest expense of $94 million and.

Our non-GAAP effective tax rate of 24%.

And an estimated diluted share count of $106 7 million shares.

Further for 2021, we expect our net cash outlay for income taxes to range from 50 million to $60 million.

I also want to provide you with some commentary for the first quarter, given our normal seasonality and current expectations for the continued pace of the recovery from COVID-19.

As Alistair highlighted we expect year over year growth to accelerate in the second quarter in both businesses as we begin to lap the 2020 impact from the pandemic.

For our clinical solutions, we expect this to be powered by the ramp in our core backlog conversion along with our Covid vaccine trials.

Our commercial solutions, we expect this growth to be driven by robust new teams start deployment solutions.

Along with continued strength in communications and consulting.

We expect first quarter revenue of $1 7 billion to $1 to $1 billion.

And total adjusted EBITDA of $141 million to $151 million.

This reflects as reported growth of <unk>, 6% to 4% compared to the first quarter of 2020.

This revenue growth includes an estimated contribution from acquisitions of approximately 490 basis points and a headwind from our 2020 divestitures of approximately 170 basis points.

This growth is also net of an expected headwind of approximately 210 basis points due to the continued slow recovery in Reimbursable expenses.

This completes our prepared remarks, and we'd be happy to answer any questions.

Operator.

Ladies and gentlemen, as a reminder to ask a question you will need to press. The Star then the one key on your Touchtone telephone.

To withdraw your question. Please press the pound key please standby, while we compile the Q&A roster.

Now first question coming from the line of Eric Coldwell with Baird. Your line is now open.

Thanks, very much and good morning, I was hoping to dig into these commercial bookings a little bit you always have fourth quarter favorable seasonality or at least that's the expectation, but this was obviously a very good number.

I'm curious if some of these awards were related to <unk>.

Anything you'd call out as sort of unique whether it's COVID-19 related therapies.

Or maybe something interesting happening in <unk>, one with some of the projects you've talked about in your recent presentations.

Or if it was really just broad based I just was hoping to dig in a little bit more on the bookings strength. Thanks, so much okay.

Good morning, Eric Alex here, Yes, we're very pleased with that obviously at one six.

In excess of one six times book to Bill for commercial is a great result.

Yes seasonality.

But.

We're always pleased to see the growth in that number and I think it's a little bit of all of the things you suggested to a certain degree.

Some COVID-19 work in.

There is which we are starting to see more and more of coming through into the commercial.

Realm.

There is a broad based efforts around the connected platform, we're winning a lot of work with our platform now as people look for a more digital approach to field teams and HCP engagement.

The investments that we've made in that technology and that and the processes and people that sits around that are important.

We're seeing good traction in full service commercial.

Yes.

Work, that's coming in from <unk>, one as you said, but also.

Just integrated full service commercial on its own so people buying the whole package from.

Michelle and her team as we go and I do think there is also a sense of optimism in that commercial space.

Around the recovery from Covid.

We're seeing vacancy management come back we're seeing teams launch we had a record year in 2020, because a number of teams launched.

And that.

A lot of that work is coming from our smid sector, where.

It's more teams, but smaller which helps us to continue to diversify the backlog so really very very broad.

Three broad basis and with.

<unk> you.

Follow on question with a robust pipeline going into Q1 of the share so very pleased with how that's shaping up.

I like how you are you.

Read my thoughts there a little bit.

Actually my real follow on question was was a little bit.

Different angle.

I think last year, we saw.

If memory serves the second best or tied for second best year of FDA approvals for new drugs.

And there was.

There's been a sense that pharma is really werent launching three new products the way. They historically did in that there were maybe delays in that traditional if you go back years ago. The original Blitz, Craig that you get upon upon approval.

I'm just curious what is the what does the backlog or the pipeline look for these newer products and what what kind of decisions our clients, making around these launches.

Is it is it really a pig in a python situation or is it no we are.

We're changing the game and we're just <unk> as you said, maybe smaller teams may be more omni channel, where going forward, but don't expect a big Blitz creeks of the past.

Yes, I think I think some of those big efforts will be day.

Seeing that little bit in 2020 some of that.

More strategic partnerships that we've won and include some of those.

But I do think it's the nature of the products that are coming through more specialty tire science.

Boots on the ground more educational more support through <unk> nurse educators to make sure that.

The physicians that are seeing the specialty patients.

Supports it very strongly in the field with everything that they need and.

In a more omnichannel way I think omni channel one of the legacies of Covid that we see is really that shift over to a more permanent shift over to a digital footprint.

In commercial launches and commercial detailing.

And the support that we give around that with the connected platform I think is really.

He's been a great <unk>.

Recent driver for us.

Yes that innovation needs to be there I mean, Michelle your thoughts.

On the style of launches now compared to where we were just a few years ago.

Yes, that's a great question and I.

Totally reiterate everything that Alistair said, but what I would add is that.

I think that customers are getting very smart about how they communicate with all of our stakeholders right and.

It's really about data and insights around different customer mix, whether it's hcp's our payers our patients.

And creating a very personalized experience for that individual and so I think what we're finding is that.

It's not one strategy anymore right. It's not these large sales teams that go out at launch.

A bunch of tactics and FERC currently on it's really very focused around creating the right message at the right time to the right.

Customer and that those customers the ROI on those individual customers are different and the relationship you need to have different customers with different though.

I think it's great for the commercial business because it diversifies the typhoon.

Solutions, we're bringing forward and.

Diversifies our backlog so do you think.

Something that.

We're uniquely positioned to address because of the breadth of our capabilities, but it also creates what I think we all want next day, which is a more diversified backlog.

Thank you very much guys I appreciate it.

Right.

And our next question coming from the line of Robert Jones with Goldman Sachs. Your line is open.

Yes. Thanks. Good morning, Thanks for taking the questions I guess, maybe just one on clinical Alastair you and your team.

Here's a consistently talked about.

Delays, but not cancellation.

As it relates to the Covid and Covid work in Covid complications from conducting trials.

Just given that dynamic could you talk a little bit more about to what degree there is really pent up clinical trial demand and as it relates to that anything you could share on how we should be thinking about backlog burn as we get into 2021.

Yes, good morning book.

Thanks for the question.

I think you said a little bit about pent up demand starting to flow through not just a Q4 book to bill but.

Those are reported ahead of us all at pretty strong book to Bill.

Sales across the space. So we're starting to see that flow from again, the smid pipeline is very strong.

And the pipeline that lagged a little bit still has large format and I think they are very cautious to come out making sure that they're not going to put people in harm's way etcetera.

We've seen that pipeline recovery, which indicates that that pent up demand is that some of it is still COVID-19 driven as well, we see we still see a fairly healthy.

Pipeline of Covid.

And our overall pipeline treatment trials as well as some vaccine trial, though.

So.

We see that coming through I think as we we start to recover from the lack of.

Site participation because of Covid right because of the weather.

The site closures youll see that burn rate pickup for us.

Rates start to pick up kind of as we go through Q2, and then accelerates into the back half of the year as those COVID-19 restrictions come off but also as the work that we won kind of from the end of 19 onwards in 2020 per as being a record year in sales.

Health is to bring that backlog through close on top of that you've got the COVID-19, our COVID-19 trials slightly.

Hi.

Probably a quarter behind where some of the others were in terms of the Covid vaccine trials coming through so you kind of get that global acceleration for us where our backlog ex COVID-19 thoughts to burn again, a higher clip because of site access et cetera, and enrollment picking up.

We got new trials, obviously built up to go on top of those going through start up now I mean, we talked about our startup figures for 150% of site activations compared to pre COVID-19.

We werent exactly hanging around before Covid now we've got this massive pilot starts at work that's starting to work its way through the model.

Charles will come on to enroll Q2 and onwards, and then you've got Covid that's kind of.

Driving a little bit extra on top so a lot of growth this year.

<unk> is a little bit steeper because of the recovery rate from COVID-19 than we'd normally expect state, but we've been preparing for that.

Recruiting slightly ahead of the curve to make sure that we can handle the growth.

An unusual year in that in that sense of the growth is so quick but it's got three or four elements that are really all tailwind.

No no. That's helpful. And then some of this might tie into my follow up but Jason if I heard the one two numbers correctly it looks like the EBITDA margin at the enterprise level.

Somewhere around 12% at the midpoint I know <unk> seasonally high but even looking back at Q3 Q that's true.

In line to below anything specific.

Might actually obviously relate suddenly think Alistair just share, but any any specific dynamics that you would point to as far as why won't you EBITDA.

Margin might be a little lower.

Hey, Bob Good morning, Yes, I mean typically.

If you go back and look we're in that sort of 12 to 12, 5% range in quarter one.

Come out of a very strong quarter for from.

On the margin.

Percentage basis, and dollars frankly, because of the push of everyone to get all of their change orders finished all the taxes have have capped out for the year.

The pay on the payroll side you have your CTO vacation reversals were.

<unk>.

Really just drive that quarter four high and then all of that resets and starts over and you have sort of this double.

Laminate quarter, one there on the cost side.

So it's really in line with what we typically see from those seasonal seasonal items and nothing really to point out that's different.

Okay got it thanks, so much.

Thanks, Bob.

Our next question is coming from the line of Tycho Peterson from Jpmorgan. Your line is open.

Hey, Thanks actually one follow up on one of Bob's questions about the recovery trend Alistair talked about site Activations net 100.

50% of pre Covid levels enrollment of 120% of pre COVID-19 levels, but obviously youre already at 70% of site accessibility. So.

I'm curious how you think about kind of resolving bottlenecks. There was the answer leveraging early more than doing more remote monitoring and making investments there to try to kind of.

Average that channel more are there ways to kind of pre that true up of bottlenecks.

Yes, yes.

Obviously, I forget the approvals in place to be able to do the <unk> piece.

At home health piece, so there are steps to do to get through that and.

And also what are the factors in those numbers, obviously is as our Covid work starts to ramp we've got a lot of COVID-19 patients and let COVID-19 sites coming through those sorts of numbers. So it skews the overall a bit. So if you look at that just keep just keep that in mind when you think about those.

These numbers.

Acceleration dose.

Have a bit of COVID-19 in it but I think.

Sites are handling issues on a local level through.

PPA and local kind of.

Protocols.

They are engaging more that getting back into the into the enrollment phase you will see COVID-19 started to clear in a lot of different countries.

On a per call.

Tuesday, this week with a customer in India, who was talking about the COVID-19 rates, they're dropping down to see that in the U S. We're seeing that in Europe.

There's a lot of optimism I think in the sites that they can get patients back in and get moving forward quicker. So.

Yes, those bottlenecks day to be managed carefully and one of the rail bottlenecks is actually the amount of time people onsite can spend on each project.

So getting a CRA from site can be a little bit more difficult, but that's where the remote monitoring access comes into clear out backlog. So you don't have to spend so much time on site.

A lot of different.

Strategies to deal with it but yes, it will be leveraging anything with to do that wherever we can.

And then you talked about debt FSP award doubling obviously scenarios one helping there now that you've got to interact can you talk a little bit more about how that may helped drive more FSP cap.

I'll take this.

Yes, well, we don't really think about FSP from interactive.

Our full service model to the emerging biotech.

But yes, I mean overall RF are very pleased with our FSP growth continues to be a tool that we use with <unk>.

Large pharma partners.

Body ready with scale.

To support either a hybrid model or just full FSP. So there's a lot of interest in that.

On the <unk> side, that's really about full service there are a few little.

Biometrics data management Fsp's that I have that we've already rolled into our major FSP effort.

Okay, and then last one you just mentioned the opportunity to leverage kinetic.

And to the clinical side.

How do you think about that is that really just to drive faster enrollment or maybe what's the opportunity there.

It's we're really excited about using Connecticut clinical we've used it now probably a half a dozen times are so big trials and the impact it has is quiet.

Barry Mark.

So we're very pleased with that as a new tool.

Or is it really helps too.

The <unk> really in the name of digital amplifier is something that helps too.

Identify trials.

On a broader and abroad away to people and referring physicians networks of physicians. So we can target and the way the technology works to make sure that.

<unk> with potential patients were actually seeing the information around trials. They are in the vicinity in general or in the specialty.

So we've seen a lot of referrals through that to actually investigative sites.

And that's been a great kind of.

Proof point of the model using our insights from commercial use we use this platform on <unk> to communicate to them and it's really it's really about audience engagement the patients, referring physicians et cetera, all in audience.

And this helps us to get the right materials in front of them at the right time, when they're receptive to finding out information that could be useful for their patients. So a great tool.

We've got a lot of interest in it from a large pharma clients.

About using it kind of across their platforms already and Thats pretty significant if you.

We now ask slowly some of our customers moving some times, but some of them have used this tool and they want it for everything that we're very very excited about that.

Great. Yes, Thank you Tycho and I just wanted to hop back on the on the FSP question. The full service I think analysis prepared remarks, he mentioned that we've seen a doubling of our full service commercial awards in 2020, which is the model we've been driving over the last several years, which things like genetic and other.

Investments, we've made I'll put the services together so think of it.

FSP on the clinical side has moved to full service.

We have a combination of both businesses, we are driving that way on the commercial side as well point solutions in the past, we're driving more towards full service commercial and overall commercial services, we've seen a doubling of those awards during 2020.

Got it thank you.

Yes.

Thanks, Doug.

Our next question coming from the line of David Windley with Jefferies. Your line is open hi.

Hi, Thanks for taking my questions good morning.

First I wanted to just a clarification kind of a housekeeping one around backlog where.

I was looking at the role in and it looks like there's a fairly substantial out of some sort maybe it's.

Maybe it's the <unk> backlog or an FX adjustment or both is that is that the kind of the plug I need to get to the $10 2 billion.

At the end of the year day bookings by themselves would do it.

That's right Dave.

You would add the center act and the billing work backlog too.

Core set yourself backlog.

And Thats, how you would get to the full $10 2 billion.

Yes.

Do you have numbers for those or I guess I can just back into the back end of the total.

Yes.

It's roughly I think.

And the.

$5 billion range for the combined.

Yes.

Okay, and then alister.

Both of you have talked about.

Ramp.

To Bob's question about first quarter.

Ramp of revenue backlog burn rate kicking in in the second quarter.

One a day and to understand that a little bit better than that.

I think youre, telling us that your site activation activity is running hot because at least in part because of Covid, which sounds to me like those are already starting to contribute in the first quarter, but the burn rate not really grow until the second quarter. So if you could just kind of flesh that out a little more I appreciate it yes.

Yes sure.

Good day from it.

Yes, Youre exactly right. So you've got the 30 startup activities going now.

The end of Q4 into through Q1, and then the real revenue starts to flow out of these trials when when those patients are enrolling the monitoring fee donor visits are being captured.

So that really starts to come on stream and the Q1 Q2 for us.

Because thats when the Covid, we get that Covid acceleration coming through from the vaccine trials that we're running.

And remember a lot of the work that we won in.

And Covid is the majority of our work in Covid is on the treatment side, which we've grown a bit more like regular trials. So they're not starting up in one month and enrolled in the next day or.

A bit more slow and steady take a couple of months to get opened up.

The enrollments a bit slower.

That spreads it out a little bit which is why our backlog accelerate through Q2 into Q3, if not immediately as we hit Q1.

Okay final question from me, Jason You mentioned in your prepared remarks.

<unk> focus on improvement in cash flow conversion and wanted to understand if youre thinking on that.

Yes, a cash.

Capex.

Declining or just further improvement in DSO is what do you think your levers are there to improve that percentage.

Yes.

Yes, so all of those things absolutely Dave in terms of continuing to.

Focus on.

Net of our DSO accounts, which is very important and you can see some of that coming through the end of the year here, particularly if you look at the deferred revenue and from what we've done there on the DSO.

Sure.

And we will continue to pay close attention to Capex.

But not we're not.

Trying to under invest in the business by any stretch.

Then the below the line items over the years as we put the companies together right. We've had to spend money to do that and launching forward bound and we're just.

Focused on all of those areas as well.

Thank you.

Mhm.

And our next question coming from John from Macquarie. Your line is now open.

Hi, Thanks, very much Alistair just following up on a comment you made about some of the Covid work a few minutes ago. What is the duration of those awards that youre seeing now across both clinical and commercial for clinical can we think of those as sort of two to three years sort of typical study or will they burn faster from your impression.

<unk>.

That's a good question.

Ill pass you over to Paul for some specifics from the second but yes, they all factor, particularly the vaccine trials I think.

Typically obviously, you're going to run a lot faster than that.

Treatment trials tend to have a bit more of a follow up on them to see the overall the long term impact talking about people with hepatic failure arrow.

<unk>.

Going long breathing respiratory issues.

There will need to be followed for a longer period, so they're a little bit more grateful in terms of timeline, so but Paul.

From the overall burn.

Kind of timelines for those trials.

Yes, no I think you're spot on there Alastair that again the treatment trials our experiences are more aligned to our normal burn rate, but certainly when you have the the vaccine trials there is a.

A faster enrollment in both indirect and direct spend on those so I think thats. The typical that we've seen I would say the bigger mill.

Mix issues will just be around therapeutic area. When you think about burn rate.

Great, Thanks, and Jason and the.

The 'twenty one guidance that you've given us from the top line can you give us a sense about what you expect COVID-19 work to contribute both in clinical and commercial.

Yeah, Hey, John Good morning, so.

Yes.

Look at the.

We will start commercial if you go back to.

One of the earlier questions I think it was Eric's question on our quarter for bookings in commercial we.

We've seen some bookings on the debt.

Covid work that we've talked about in prior quarters, but nothing major yet from that those are those are still out for approvals. So we're doing some prelaunch work, that's coming through but it's immaterial, but the larger bookings and the revenue from that would be.

I would say more second quarter, even second half on 'twenty one.

So not too too much there in addition to some of the work we've done.

Which has been less than.

Yes, probably $25 million in communications and consulting for Covid in 2020, so nothing material there and on the clinical side.

Not.

In 2020, we talked about the awards being less than 7%.

<unk> is even less than 5% less close to 4% if even that.

And the revenue has been quite low in 2020, as well again, probably less than $25 million.

That does go up quite a bit as we go through the trials that are now launching starting.

We haven't guided exactly are provided insight into that but it is a substantial part of the ramp from two two onwards, but we just haven't provided specific numbers on that.

And then Alex from maybe one more last quick one with another year under your belt post merger.

Or your latest experience around sort of integrated wins are you seeing those go up or down as a percentage of the total and are you still seeing those primarily in your sort of Smith client base.

Yes.

Good question, So integrated wins from me fall into a couple of categories now broad based.

Large client kind of cross sells.

Where we're penetrating customers day in clinical with commercial particularly around communications and consulting.

And vice versa, but then obviously the <unk> platform continues to gain traction in the smid base certainly.

We've got one big partner, who uses that model as well, which is exciting and then I think the.

Area that we've seen the most growth which is it goes back to <unk> question, a little bit about where we saw double is full service commercial we saw full service commercial.

Packages double in 2020 over what we've done in 2019, and I think Thats a model that will gain traction normal so.

As we move into that more.

A full service commercial launch phase so, yes, very excited about those things.

Great. Thank you.

Thanks, Sean.

Thanks, John.

And our next question coming from the line of Patrick Donnelly with Citi. Your line is open.

Okay.

Great. Thanks for taking my questions guys.

Maybe Jason just on the Reimbursable expenses part I know you talked about a remaining a headwind in <unk> can you just talk about that sequentially and then also kind of the split between commercial and clinical we feel pretty similar between the two.

Hey, Patrick it's difficult to hear you are cutting in and out I don't know if its smartphone are not debt.

Reimbursable.

I mean, it's been.

Disproportionately impacting commercial but it's been impacting both businesses sequentially. When you think about just an organic basis.

We've seen that step up.

Quarter to quarter three quarter, four and we expect to see that again in quarter. One in terms of the sequential reimbursable, but both businesses still being impacted year on year from quarter, one of last year, where we were.

Pre COVID-19.

So that's that's a big driver if you if you just sort of back out the reimbursable expense impacts from quarter. One I mean, the business is largely flat. So that's a pretty big impact is as we outlined and then we expect to see that continue to growth throughout the year.

When we get.

Hopefully through everything first half and we'll see it continue to go up in the back half, but we don't anticipate as we've said earlier.

And I guess in quarter three call that we will ever see it back to the percentage.

Our total revenue that it was pre COVID-19 just given the changes in <unk>.

Monitoring and.

Detailing et cetera.

The digital capabilities that are now.

And the commercial business.

Okay. That's helpful and then Alex maybe one for you I know you guys had talked about bringing the leverage ratio down to three three and a half by year end.

How should we think about capital deployment M&A this year, given given the balance there.

Yes, I mean, we want to remain opportunistic.

As we go forward.

<unk> for US is to continue to pay down debt and we've been bringing leverage down over the last two or three years.

On that basis.

Yes.

If there are deals to be done and help us drive towards strategic goals.

Like we did with interaction anything with we're going to we're going to be interested in taking a look at those kind of tuck in level deals that can take it into a high growth market or can open up channel as far as like getting with dose.

Our priority is going to be paying down the debt, obviously, but yes, we would still be open to.

More deals like that or if there was something geographically we wanted to do.

We'd look at that as well.

Alright, thanks, guys.

Thanks Pat.

Thanks, Patrick our next question coming from the line of Erin Wright with Credit Suisse. Your line is now open.

Great. Thanks can you talk about the sustainability index strength that we've seen in real world evidence.

Slightly in the quarter and what your expectations are for the durability of that strength.

In 2021.

Got it.

Lately.

Yes.

Yes, good morning, Yeah, we got from our questions.

J P M around railroad evidence and it is a very interesting space.

<unk>.

Grown a very good capability there from a smaller base.

So a great growth last year I think it was our fastest growing organic.

Group.

So we're interested to keep hiring in that space, we've had a lot of success, bringing into into that group from the.

The <unk> as well as pharma and I think it's really really important space to hire people in from.

Large pharma who are.

Typically the biggest customer of that of that.

Kind of service I do think it's going to be a growth area for the next several years not just 2021.

And I think COVID-19 will fuel as well as the bulk of patients they're going to need longer term follow either those that were in the vaccine trials are those that are in.

Some kind of deficit from along Coca.

The call along Covid or who have been in a trial.

To look at some of the treatment impacts.

Because governments need to see lots more data on these patients because a lot of it wasn't collected as they went through phase III because of the speed. So I think that will fuel demand in the long term follow up railroad space as well as people looking at data using data to answer the questions that come back from regular.

So you see organizations, who got the capability to produce regulatory grade.

Submission packages, we work with.

Constant AI on that kind of thing in the oncology space, so that the ability to pull that data together and then look at the gaps that you still have to answer a question from the regulator is going to be a big part of that railroad growth as well.

Okay. Great. That's helpful. And then can you speak a little bit about the acquisition of <unk> work and how much that adds to topline growth continuously that was all embedded in guidance.

Margin profile as well as the customer base profile any overlap there.

We anticipate meaningful near term stepped up investment associated with New York congestion around decentralized.

I'll go to try and remember all of that question there.

So.

I think I'll start with customer profile.

Along with a pretty small organization in comparison to the largest finance right, but one of the things that we immediately track to its customer base day work with all the big Thomas globally.

So your access to new contacts a channel through that as well so thats.

A good element of that yes, we will continue to investing in them with obviously, we will be bringing them onto some of our systems, but we can I use them as an independent business unit that will have some of the sales rose as customers too so.

The conversations with those and it's acquired rare asset. So we have debt will obviously be delivering for other railroads as well as direct pharma customers.

But also being able to introduce that to our smid customers. We were dealing with with outsource work toiling with <unk> had a good relationship and they do great work, which was a big driver of the acquisition itself.

We will continue to invest in it yes, the numbers have been incorporated into the overall guidance.

And it's a fast growing area I think fueled by Covid, but it was a fast growing area before COVID-19 as well so.

We want to make sure that we write that as as we implemented as part of our decentralized trial approach.

It's so great and while having the right technologies to do decentralized trials.

Still got to go and check on those patients, albeit goes to the home.

Illingworth gives us the capacity and the reach to do that on a lot of trials that a lot of locations. So we're very excited to be able to bring that to customers.

Option.

People are a little bit more reluctant to go to a trial site or go to a hospital for treatment. If it can be delivered at home. We can now do that so we're excited about that I think that COVID-19 at all.

Did I Miss anything.

Great. Thank you.

[laughter].

Our next question coming from the line of Elizabeth Anderson with Evercore ISI. Your line is open.

Hi, Good morning, guys moving to sort of a follow on to Aaron's question, how our sponsors thinking about 10 months.

Remote patient monitoring and remote trials as we move out of Covid would you say that.

Stopgap measure I think you are willing to engage in the trial.

We'll see how that had changed yes, Richard is moving.

For the post Covid World.

Yes.

Great Great question.

Obviously, it was used as a big stop gap.

At the highest COVID-19.

Sure.

But now it's been something we've been pushing.

<unk> also as I think as the CRO industry for a while to customers that we can do remote monitoring et cetera, we've certainly been very active on an ACL road on these discussions.

And talking directly with FDA on it.

The reluctance has always been customers are worried about what the regulator will think of data that's being monitored more remotely.

But I think a lot of those concerns are now put to.

Bed because this has been a big test there's been no real the IFC in anyway, no real big quality issues.

Associated with remote monitoring so it can be a strategy I don't think it takes over I think it becomes an adjunct to a well known as the trial. So.

Maybe you have several visits within an overall program that cannot be done remotely or through telemedicine rather than.

Having to have a patient from all the way into assai et cetera, particularly if there are a lot of visit maybe some of those visits can be done remotely. So I think that you'll end up with a hybrid where you still have a lot of in person.

Trial work at the site.

<unk> bye.

Remote monitoring or alternatively, all done from home.

In the home health.

Channel.

If we can add services living with.

So I think it becomes.

It's here to stay I think if.

If you look to trials I think kicks in 2019.

3% of them had.

A high level of digital implementation I expect that to go to <unk>.

20% over the next four or five years, you have to design these things into new trials as it comes through.

Yes, we will see more and more.

But I think we and all the like as true very prepared to be able to deliver that.

That makes sense. Thank you.

Thanks Lou.

And our next question coming from the line of Sandy Draper with Joy Securities. Your line is open.

Hi, Thanks, This is stan on for Sandy.

Maybe we can keep the distributed trough and going here.

Im just thinking about obviously distribute distribution, we're proud of that kind of flip the script from a quantity of sites that you are working with how do you think about maybe the capacity to handle more of a distributor trial type of environment is there a theoretical ceiling to how many trials can handle that haven't distributed component to them.

Good question.

I think so.

Obviously.

On the home health channel Alienware, because the smaller organization, but we tap into big home health networks.

Big home Health nurse network, so the capacity for that pretty good and it can expand scale very rapidly.

So in that sense no.

Remote monitoring actually take some of the burden down on the site. So I think.

Assai designs as far as trial design mature.

And maybe incorporate a little bit more remote and a little bit more home health. It probably takes a little bit more pressure off of the inputs and monitoring.

Are those resources have been pretty standard over the years.

As always a bit of accounted for in there so.

I think probably helps rather than hinders in a way and helps us service more down because you've got two or three channel potentially within any one trial enrollment in one single channel.

Got it that's helpful. Maybe one more from me on <unk>.

Just curious about your integration plans is the plan here to fully roll off.

And to your core operations with an operating separately.

Maybe how does the go to market strategy really.

In the same way as a separate or is it going to be integrated with the core sales offerings.

Yes.

We're holding it as a separate business unit, which.

Services are emerging biotech group and I think the best interact team.

<unk> since they joined us.

In working out how they plug in.

What we saw in due diligence with them was a very different customer base.

And their customer base once that agility, they don't need the big kind of the institutional hammer that <unk> health can be sometimes but they will not nimbleness and the project team on that.

Net contact.

Hi, touch kind of <unk>.

Engagement and we do a lot of that with our smid clients, but all of our Smith clients, they're quite big now.

They need that structure.

The <unk> group.

That more agile boutique kind of CRA fail. So we're trying to maintain that obviously the backend the G&A.

To be integrated now and where we can support from a functional perspective.

Salto biometrics et cetera, that's coming together.

But also one of the one of the big elements of working with <unk> right.

They have had.

It had a limited geographic footprint really to western Europe.

The U S.

North America I should say so when they won work that was truly global which they do win quite a lot of that.

We weren't able to service all of that work in Japan, and Asia, and Latin America, and what we do know for them is we all day network. So everyone has to reverse.

Got a couple of million books, with the monitoring out in Japan, or China, or Argentina, or wherever it may be we now do that work for them.

It was a good revenue synergy day between the organizations to as we build so we'll keep that as a separate business unit targeting.

Not high paced high growth.

Emerging biotech sector and.

Is integrating well.

So far.

Got it thank you.

Thank you.

And our next question coming from the line of Dan Brennan with UBS. Your line is now open.

Great. Thanks for thanks for taking the questions.

I may have missed it data analysis, so different from to the outlet for 'twenty, one could you discuss kind.

Kind of clinical versus commercial what to expect there and then I know the burn came up a few times, Jason but what would the clinical outlook combined with the burn rate as we go through the year.

Yeah, Hey, Dan.

We haven't talked specifically about clinical versus commercial.

But when you look at obviously Center act, enabling work from the contributions.

Talk about there on the M&A side.

That's clinical and then if you look organically with without.

All the divestiture activity that has happened.

Because we've had a divestitures of contingent staffing and clinical and then the medication adherence and commercial.

Think about commercial being yes.

Above the sort of organic.

Growth rates that we've talked about in the business and clinical as well. So I mean, thats kind of a steer of how we're looking at strong years as Alister said for both segments.

On the on the burn rate on the clinical side.

We've talked about how we bottomed in quarter two.

Even an eight 7% has come up to that 90 293 range.

Typical seasonality in quarter, one that we see every year, where the Bart rate can step down plus we've had strong awards that just mathematically can cause it to step down so it will step down some in quarter, one as we've outlined and then start to recover again.

Through Q2 and through the back half.

But not getting back up to that.

11, 11, 5% given we've seen our average study period extend from yes.

Low 50 months 60 months, given all of the oncology in phase III work that we're letting so that's how we're looking at it thinking about it.

On the burn rate side.

Great. Thank you and then maybe within commercial could you just give us a little bit more color on deployment and communication.

How we're thinking about the outlook in 'twenty one there.

And it will be talked about from farmer sales head count reductions that they're anticipating in 'twenty. One are you seeing anything on that front or is that factored into guidance. Thank you.

Yes.

Consulting has been growing continue to grow just really strong business the communications business.

<unk> has been performing really well winning a lot of new work.

And really starting to hit.

Hit their stride, there and deployment solutions I think michelle's talked about Alastair talked about we launched a record number of teams.

In 2020, and we will continue to see that this year and Thats before we start seeing the <unk> come in that we've talked about the COVID-19 opportunities that if they are approved.

So really all businesses doing well and.

We expect to grow and then Michelle I'll, let you talk a little bit about the.

The reps.

<unk> discussion.

Sure.

It's a great question so.

One thing I always say is that there's more than one CRM company.

They have to how that's managing market share between companies in CRM, but I can't speak to that.

That but the jumps that that means that there is a reduction in overall sales representative I don't know if you can make that leap I think what we're seeing is a diversity in the types of people that pharma needs to launch their brands right. So you hear us talk about nurse educators clinical trial <unk>.

On.

Reimbursement specialists et cetera, with the way the FDA is approving.

New products I think it was 57% and 2020 day.

Tend to be more specialty products and they're more complex. So the types of people calling on customers is a much more.

Diverse group of background and then when you layer on the fact that we have been very successful in enabling them to be fully digitally enabled and virtually enabled and orchestrate everything.

Managing their HCP interactions.

<unk> net.

It's just a different type of commercial model launch so overall.

We have seen a lot of interest in the business and we see.

Starting new teams. So that's I think as Jason said, we had a record number of teams start in 2020.

We also because of our full service commercial which is another piece of information and we have good line of sight between finance line in full service commercial.

Brands that we're currently doing clinical and I'm sorry.

Consulting and communications work on that have not launch teams, yet and it's not in our backlog or is that an hour.

And it's not an all in cost of warrant targets, yet because it 12 months out and so we have good line of sight to that as well so.

We feel very strongly that our business that's not the case.

Great and then if I could sneak one more in.

With the very incentive come up.

There's likely a longer tail to a lot of the corporate records being done.

Would you care to give us your view I think COVID-19 bookings from 7% of total in 'twenty, one like what do you think that shakes out in 'twenty two from the pipeline.

Yeah.

Less than 10% of bookings in 2020, what do you think that shakes out for this year given the pipeline of demand that youre likely from now for additional Covid work.

Yes, Thats good question.

Yeah.

I think.

With the variance that we're seeing and.

Moving into long term follow up real world.

I could see it being I could see the pipeline staying roughly where it is growth quarter or two more.

And then.

It depends what happens with the virus right I mean in all previous pandemic like this you see two peaks and then fizzled away we've had that compete largely.

Seeing lots of.

Virus numbers dropping in around around the globe, either through Lockdowns zone, or a little bit more naturally.

So there's a lot there's a lot of environmental factors to kind of pick a number around that.

I think we'll see a continued kind of RFP flow in and around Covid for several quarters, yet probably possibly through the end of the year.

And maybe even into 2020, it's just hard to call at the moment.

Where that goes it goes.

Yes.

If everybody gets handled vaccine rollouts of successful does that demand drop away I don't know.

Will do you see more demand for ongoing longer Covid long long Covid trial, again, I think probably yes, but I just don't know to what level.

So it's a really hard question to answer I think.

Great No that was very helpful. Thanks again.

Thanks, Dan.

Thanks, Tom.

Our next question coming from the line of Jack Meehan with Nephron Research. Your line is open.

Thank you good morning.

I wanted to continue on the vaccine work it sounds like you've won some more business from the last time, we spoke just to clarify is any of this OWS related.

Then just thoughts around given we have the approved vaccines and there is some variance out there just the level of visibility into this work progressing.

It's built into the ramp.

Any risk around cancellations, just your thoughts around that.

Yes, Thanks Jack.

So I think the answer to the OWS is no. We've worked on some of the AWS things in terms of functional support data management analysis et cetera.

And the new work that we're working on is tends to be not that these smaller companies.

Non U S entities, so kind of more global work.

Yes, with the profile I mean, the majority of our work is is the treatment.

On the treatment side. So there's obviously a lot of that going on good access to patients we're seeing good enrollment in those trials on.

On the vaccine side I mean, I think the vaccine trials that we've got open going are enrolling well, there's still a lot of even though the numbers are trending down in several western markets you still got a lot of COVID-19 in other locations. So these are global trials.

Where we're seeing a lot of enrollment.

Yes.

Around the Globe, Latin America, Asia et cetera.

So yes, I mean, if it's the vaccines were well and Theres vaccine equity so ultra old site. All countries are getting good vaccine program going distributed.

Then, yes, there'll be it will be harvest volume patients as we go out which is great right. That's kind of what we won almost as a society. That's what we do one of the society.

But we'll deal with that as we go.

You got to stay flexible and be able to move to different sites, where there is low collaborate so it's countries without a high level.

I appreciate it and Jason one clarification for the first quarter guide for the two segments I. Appreciate all the qualitative commentary you gave there was obviously a lot of moving parts with M&A divestitures FX reimbursed expenses.

Wondering if you can just help us with maybe some revenue ranges for clinical and commercial for the first quarter.

Yes.

So.

I guess, we're not.

Officially guiding Jack Bye.

By segment, just given the integrated nature of all we're doing these days.

Yes.

<unk>, one and the different full service product development capabilities, you're dropping in but I think the way.

<unk>.

Think about it is.

With Reimbursable.

Performing the way they are these team standing up.

On the commercial side think of that sort of.

Flattish to down a little bit.

Sequentially.

Just given seasonality and then clinical is obviously going to be when you think about core <unk> plus the.

Plus the acquisitions.

Okay.

Yes, that's helpful. Jack Okay.

I mean, I think that will help you suffer.

Getting to the to the range there.

That's all the time, we have for questions today, I will now turn the call back over to Mr. Allison Mcdonald for closing remarks.

Okay. Thank you so our sincere thanks to the entire <unk> team.

For all they've done in the face of these unprecedented conditions that we faced over 2020, we remain very confident in our market positioning and look forward to strong growth and profitability in 2021 as the recovery from COVID-19 continues but thanks for your attendance today, everybody and be continued interest and investment in our organization. Please be safe and have a great day and be good.

See you soon thank you.

Ladies and gentlemen that does conclude our conference call today. Thank you for your participation you may all disconnect.

Okay.

[music].

Yes.

Okay.

[music].

Yes.

[music] zone.

Yes.

Got it.

Yes.

[music].

Sure.

[music].

Okay.

[music].

Yes.

Okay.

Yes.

Okay.

Yes.

Yeah.

Okay.

Sure.

[music].

Yes.

Okay.

Yes.

Okay.

Yes.

Thank you.

[music].

Okay.

[music].

Okay.

Yes.

[music].

Okay.

[music].

Sure.

Okay.

Yes.

Okay.

[music].

Okay.

Yes.

Okay.

Yes.

Sure.

Yes.

Thank you.

Okay.

Yes.

[music].

Okay.

Thanks.

Yes.

Okay.

Yes.

[music].

Please proceed.

Yes.

[music].

Good day.

Yes.

Sure.

Okay.

Alright.

Sure.

Yes.

[music].

Okay.

[music].

Okay.

[music].

Okay.

[music].

Yes.

Okay.

[music].

Yes.

[music].

Sure.

Yes.

[music].

Yes.

Sure.

Okay.

Yes.

Okay.

Sure.

Yes.

Okay.

Alright.

Sure.

Yes.

Okay.

Yes.

Okay.

Sure.

Yes.

Okay.

[music].

Okay.

[music].

Okay.

Yes.

Sure.

[music].

Yes.

[music].

Yes.

Yeah.

Okay.

[music].

Okay.

Yes.

Okay.

[music].

Okay.

[music] expense.

Yes.

Okay.

Yes.

<unk>.

Okay.

Thank you.

[music].

Okay.

Moving.

Okay.

Yes.

Okay.

[music].

Okay.

Yes.

[music].

Okay.

Yes.

Okay.

Sure.

Okay.

Sure.

Okay.

Yes.

True.

Okay.

Thanks.

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

Okay.

<unk>.

True.

Okay.

Yes.

Okay.

Sure.

Okay.

Yes.

Sure.

Okay.

Yes.

Thanks.

Okay.

True.

Sure.

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

Okay.

Thank you.

Yes.

Okay.

Sure.

Okay.

Yes.

Okay.

Yes.

Okay.

Thank you.

Yes.

Okay.

Yes.

Thanks.

Yes.

Okay.

Sure.

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

Okay.

<unk>.

Yes.

Okay.

Yes.

Okay.

Right.

Yes.

Okay.

Yes.

Okay.

Yes.

Okay.

Sure.

Okay.

Yes.

Okay.

Sure.

Okay.

Yes.

Sure.

Thanks.

Okay.

Yes.

Hum.

From.

Hum.

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

Okay.

Great.

Yes.

Okay.

Sure.

Okay.

Yes.

Okay.

Yes.

Okay.

Sure.

Yes.

[music].

Yes.

Sure.

Okay.

Yes.

Okay.

Yes.

Thanks.

Okay.

Yes.

Sure.

Okay.

Thank you.

Yes.

Thank you.

Yes.

Sure.

Okay.

[music].

Q4 2020 Syneos Health Inc Earnings Call

Request a DemoDemo

SYNH

Syneos Health Inc

Earnings